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Interactions between steroid hormone receptors and signal transducer and activator of transcription (Stat)-
mediated signaling pathways have already been described. In the present study, we explored the capacity of
progestins to modulate Stat3 transcriptional activation in an experimental model of hormonal carcinogenesis
in which the synthetic progestin medroxyprogesterone acetate (MPA) induced mammary adenocarcinomas in
BALB/c mice and in the human breast cancer cell line T47D. We found that C4HD epithelial cells, from the
MPA-induced mammary tumor model, expressed Stat3 and that MPA treatment of C4HD cells up-regulated
Stat3 protein expression. In addition, MPA induced rapid, nongenomic Stat3, Jak1, and Jak2 tyrosine phos-
phorylation in C4HD and T47D cells. MPA treatment of C4HD cells also resulted in rapid c-Src tyrosine
phosphorylation. These effects were completely abolished by the progestin antagonist RU486. Abrogation of
Jak1 and Jak2 activity by transient transfection of C4HD cells with dominant negative (DN) Jak1 or DN Jak2
vectors, or inhibition of Src activity by preincubation of cells with the Src family kinase inhibitor PP2, blocked
the capacity of MPA to induce Stat3 phosphorylation. Treatment of C4HD cells with MPA induced Stat3
binding to DNA. In addition, MPA promoted strong Stat3 transcriptional activation in C4HD and T47D cells
that was inhibited by RU486 and by blockage of Jak1, Jak2, and Src activities. To investigate the correlation
between MPA-induced Stat3 activation and cell growth, C4HD cells were transiently transfected with a DN
Stat3 expression vector, Stat3Y705-F, or with a constitutively activated Stat3 mutant, Stat3-C. While expres-
sion of Stat3Y705-F mutant had an inhibitory effect on MPA-induced growth of C4HD cells, transfection with
the constitutively activated Stat3-C vector resulted in MPA-independent proliferation. Finally, we addressed
the effect of targeting Stat3 in in vivo growth of C4HD breast tumors. Blockage of Stat3 activation by
transfection of C4HD cells with the DN Stat3Y705-F expression vector significantly inhibited these cells’ ability
to form tumors in syngeneic mice. Our results have for the first time demonstrated that progestins are able to
induce Stat3 transcriptional activation, which is in turn an obligatory requirement for progestin stimulation
of both in vitro and in vivo breast cancer growth.
Progesterone regulates diverse biological effects in a broad
range of tissues, mostly by interaction with the classical pro-
gesterone receptor (PR), a member of the nuclear receptor
superfamily of ligand-dependent transcription factors. Partic-
ularly in the mammary gland, progesterone plays a key role in
the control of cell proliferation and differentiation (31 and
references within). Accumulated evidence also indicates that
progestins are involved in controlling mammary gland tumor-
igenesis, both in women and in animal models (6, 8, 15, 21, 24,
26, 31, 32, 48). Although the mechanisms by which progestins
stimulate growth of breast cancer cells have not been com-
pletely deciphered, several lines of evidence (6, 26, 33), includ-
ing our own work (3, 4, 25, 44), have shown that convergence
between progestins and growth factor (GF) signaling pathways
mediates proliferative effects of progestins in mammary tumor
cells.
In addition to their direct transcriptional effects, rapid or
nongenomic biological effects of progestins have been de-
scribed in several species, including fish, amphibian, and mam-
malian (27). Whether the recently cloned membrane PR from
humans and other vertebrates (59) is involved in mediating
nongenomic progestin effects in mammalians remains to be
elucidated. Nongenomic effects of progestins in breast cancer
cells have been unraveled by startling reports from Auricchio
and coworkers (5, 13, 33), who demonstrated that progestin
treatment of human breast cancer T47D cells activates the
signal-transducing c-Src/p21ras/MAPK pathway, which results
in cell proliferation (5, 13, 33). Progestin activation of the
c-Src/p21ras/MAPK pathway has also been described by Ed-
wards and coworkers (6), who further explored mechanisms
involved in progestin modulation of c-Src activity.
Over the last years, a unique family of proteins, the signal
transducers and activators of transcription (Stats), was found
to be involved in cross talks with both steroid hormones and
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GF signaling pathways. There are seven Stat genes in mam-
mals, Stat1, Stat2, Stat3, Stat4, Stat5a, Stat5b, and Stat6 (9).
They have dual functions: as signaling molecules in the cyto-
plasm and as transcription factors following nuclear transloca-
tion (9, 55). Cytoplasmic Stats were found to be recruited to
and activated either by tyrosine kinase receptors (RTKs), after
binding of GFs (38, 42, 50), or by soluble tyrosine kinases of
the Janus (JAK) and Src kinase families, after binding of cy-
tokines to their receptors (16, 52). Tyrosine-phosphorylated
Stats then dimerize and translocate to the nucleus, where they
bind DNA and regulate gene transcription.
Interaction between steroid hormone receptors and Stat-
mediated pathways has a bidirectional nature, where steroid
hormone receptors regulate Stat-dependent transcription and
where, conversely, Stats are able to modulate steroid hormone-
mediated transcription (18, 51, 58). Functional interactions
between progestins and Stats were demonstrated by Lange et
al. (26) and Richer et al. (43), who found that treatment of
T47D human breast cancer cells with the synthetic progestin
R5020 resulted in up-regulation of Stat3 and Stat5 protein
levels. In addition, these authors described constitutive associ-
ation between Stat5 and PRB in HeLa cells transfected with
the B isoform of PR (43). Recently, progesterone was found to
induce Stat5a expression in MDA-MB-231 breast cancer cells
transfected with PR (29). Progesterone also enhanced Stat3
cytoplasmic stores in the decidualized mesometrium during
pregnancy in rats (30), an effect which was inhibited by the
progestin antagonist RU486, showing that Stat3 is a progest-
erone-dependent protein. On the other hand, involvement of
different RTKs in the activation of Stat proteins has been
reported. The best elucidated are the roles of the epidermal
growth factor receptor (EGF-R/ErbB-1) (38, 42) and the plate-
let-derived growth factor receptor (50). Interestingly, constitu-
tive activation of Stats, especially of Stat3 and Stat5, has been
found in transformed cells and in a variety of human tumor
types, supporting the concept that Stats play a role in malig-
nant transformation (55).
We have already exhaustively characterized mechanisms of
progestin-induced growth in an experimental model of hor-
monal carcinogenesis in which the synthetic progestin me-
droxyprogesterone acetate (MPA) induced mammary adeno-
carcinomas in female BALB/c mice (3, 4, 25, 44). In the
present study, we addressed the question of whether Stats
might play a role in the scenario of progestin-induced growth
of breast cancer. We focused our present study on Stat3 not
only because accumulated evidence indicates that its activation
is associated with cell transformation (9, 11, 55) but also be-
cause tumor-derived cell lines or samples from human breast
cancer frequently contain activated forms of Stat3 (12, 20, 28,
53). Our findings have for the first time demonstrated that
progestins are able to induce Stat3 transcriptional activation in
both mouse and human mammary tumor cells by a mechanism
requiring Jak and c-Src activities. We also found that the pres-
ence of activated Stat3 is a requisite for progestin stimulation
of in vitro and in vivo breast cancer growth. Moreover, in the
course of our studies of the molecular mechanisms involved in
progestin-induced Stat3 activation, we unfolded several rapid,
nongenomic progestin effects. Thus, we have here for the first
time described the ability of progestin to induce rapid Jak1,
Jak2, and Stat3 tyrosine phosphorylation.
MATERIALS AND METHODS
Animals and tumors. Experiments were carried out with virgin female BALB/c
mice raised at the Institute of Biology and Experimental Medicine of Buenos
Aires. All animal studies were conducted in accordance with the highest stan-
dards of animal care as outlined in the National Institutes of Health Guide for
the Care and Use of Laboratory Animals and were approved by the Institute of
Biology and Experimental Medicine Animal Research Committee. Hormone-
dependent ductal tumor line C4HD originated in mice treated with 40 mg MPA
every 3 months for 1 year and has been maintained by serial transplantation in
animals treated with a 40-mg subcutaneous (s.c.) MPA depot in the flank oppo-
site the tumor inoculum (3, 4, 25, 44). The C4HD tumor line is of ductal origin,
expresses PR and estrogen receptor (3, 4, 25, 44), and lacks glucocorticoid
receptor and EGF-R/ErbB-1 expression (4, 25).
Cell culture and treatments. Primary cultures of epithelial cells from C4HD
tumors growing in MPA-treated mice were performed as previously described (3,
4, 25, 44). Cells were incubated in Dulbecco modified Eagle medium (DMEM)-
F12 (without phenol red, with 100 U/ml penicillin, and with 100 /ml strepto-
mycin) with 0.1% charcoal-stripped fetal calf serum (ChFCS) in the presence or
absence of 10 nM MPA and MPA–10 nM RU486. To block c-Src activation,
4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) (10 M,
dissolved in 1:2,000 dimethyl sulfoxide) was added to cells 90 min before incu-
bation with MPA. Controls were performed in order to verify that dimethyl
sulfoxide (1:2,000) did not modify MPA-modulated c-Src tyrosine phosphoryla-
tion. Proliferation of C4HD cells was evaluated by propidium iodide (PI) staining
and flow cytometry analysis, as described below. T47D cells were obtained from
the American Type Culture Collection. T47D-Y cells were a generous gift from
K. Horwitz (University of Colorado Health Sciences Center, Denver). LM3 cells
were cultured as previously described (40). In experiments assessing the effect of
MPA on Stat3 activity, T47D, T47D-Y, and LM3 cells were cultured in DMEM
(without phenol red) supplemented with 0.1% ChFCS and subjected to the
treatments described above for C4HD cells.
Transient transfections. In experiments assessing the roles of Jak1 and Jak2 in
MPA-induced effects on Stat3, C4HD and T47D cells were transiently trans-
fected with 2 g of a dominant negative (DN) Jak1 vector or with 2 g of a DN
Jak2 vector (38, 39), kindly provided by O. Silvennoinen (Tampere University
Hospital, Finland) via N. Hynes (Friedrich Miescher Institute, Basel, Switzer-
land). C4HD cells were transfected for 48 h in DMEM-F12 supplemented with
10 nM MPA and 2.5% ChFCS, and T47D cells were transfected for 48 h in
DMEM with 10% ChFCS without antibiotics. The Fugene 6 transfection reagent
technique (Roche Biochemicals) was used in accordance with the manufacturer’s
instructions. After transfection, cells were washed and cultured for 24 h in 0.1%
ChFCS before treatment with MPA for the indicated times. Total cell lysates
were then prepared as described below for use in Western blot assays. To study
the role of Stat3 in proliferation, C4HD cells were transiently transfected, as
described above, for 48 h with 2 g of a DN Stat3 expression vector, Stat3Y705-F
(10, 23, 28), which carries a tyrosine-to-phenylalanine substitution at codon 705
that reduces phosphorylation on tyrosine of the wild-type Stat3 protein, there-
fore inhibiting both dimerization and DNA binding of Stat3. C4HD cells were
also transfected with 2 g of a constitutively activated Stat3 mutant, Stat3-C,
which dimerizes spontaneously, binds to DNA, and activates transcription (11).
Both were kindly provided by J. Darnell (New York, NY). As a control, cells
were transfected with 2 g of the empty pRc/CMV vector. After transfection,
cells were washed and cultured for 24 h in 0.1% ChFCS before treatment with
MPA for 48 h. Cells were then harvested for flow cytometry. Transfection
efficiency in C4HD cells was evaluated using the pEGFP-N1 vector (BD Bio-
sciences Clontech, Palo Alto, CA) and determined by the percentage of cells that
exhibited green fluorescence 24 h after transfection. Green fluorescent protein
was visualized by direct fluorescence imaging using a Nikon Eclipse E800 con-
focal laser microscopy system (Nikon Instruments, Inc., Melville, NY). In C4HD
cells, fluorescence intensities were also measured by fluorescence-activated cell
sorter. To investigate the capacity of MPA to induce the transcriptional activa-
tion of Stat3, C4HD and T47D cells were transiently transfected with 2 g of a
luciferase reporter plasmid containing four copies of the m67 high-affinity bind-
ing site (11, 56) and 1 g of a -galactosidase expression plasmid, CMV-gal
(Clontech, Palo Alto, CA), used to correct variations in transfection efficiency.
As a control, cells were also transfected with a pTATA-Luc reporter lacking the
m67 insertion (11, 56). In experiments assessing the role of Jaks in Stat3 tran-
scriptional activation, cells were cotransfected with 2 g DN Jak1 or 2 g DN
Jak2 expression vector. The total amount of transfected DNA was standardized
by adding the pTATA-Luc reporter lacking the m67 insertion. Cells were then
treated with MPA or MPA-RU486 or preincubated with the c-Src inhibitor PP2
for 90 min and then treated with MPA for 48 h or were left untreated growing
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in ChFCS. Cells were washed once with phosphate-buffered saline without cal-
cium and magnesium and then harvested and lysed in 1 reporter buffer (Pro-
mega, Madison, Wis.) using one freeze-thaw cycle. Protein concentrations were
determined using a Bio-Rad kit (Bio-Rad, Hercules, CA). Luciferase results
were calculated as the ratio of luciferase activity per unit of -galactosidase
activity. Duplicate samples were analyzed for each datum point.
Cell cycle analysis. Primary cultures of C4HD cells subjected to the different
treatments described in Results were harvested for flow cytometric analysis and
fixed in 70% ethanol for 24 h at 4°C. They were washed twice with phosphate-
buffered saline, followed by RNA digestion (RNase A at 50 U/ml) and PI (20
g/ml) staining for 30 min at room temperature in the dark. Cell cycle analysis
was performed using a FACScalibur flow cytometer (Becton-Dickinson, Moun-
tain View, CA) and Modfit LT software.
Apoptosis assays. C4HD cells were transiently transfected with the DN Stat3
expression vector Stat3Y705-F or with the empty pRc/CMV vector as described
above. Apoptosis was investigated through cell surface binding of fluorescent
Annexin V by using the fluorescein isothiocyanate-annexin V binding assay (Im-
munotech).
Western blot analysis and immunoprecipitation assays. Lysates were pre-
pared from C4HD or T47D cells subjected to the different treatments described
in each experiment. Cells were lysed in buffer containing 50 mM Tris (pH 7.4),
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 0.5% Nonidet P-40,
1 mM Mg2Cl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 10 g/ml leupeptin,
5 g/ml pepstatin, 5 g/ml aprotinin, 1 mM sodium orthovanadate, 5 mM NaF,
20 mM sodium molybdate, and 5 mM sodium pyrophosphate. Lysates were
centrifuged at 40,000  g for 40 min at 4°C, and protein content in the super-
natant was determined using a Bio-Rad kit (Bio-Rad, Richmond, CA). Proteins
were solubilized in sample buffer (60 mM Tris-HCl [pH 6.8], 2% sodium dodecyl
sulfate [SDS], 10% glycerol, 0.01% bromophenol blue) and subjected to SDS-
polyacrylamide gel electrophoresis (PAGE). Proteins were electroblotted onto
nitrocellulose. Membranes were immunoblotted with the following antibodies:
phosphotyrosine Stat3 (B-7), total Stat3 (C-20), phosphotyrosine Stat1 (A-2),
total Stat1 (E-23), c-Src (N-16), phosphotyrosine Jak1 (Tyr1022/1023), total Jak1
(HR-785), the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI-3K)
(Z-8), and Bcl-xL (S-18), all from Santa Cruz Biotechnology (Santa Cruz, CA),
phosphotyrosine Src (Tyr416) and phosphotyrosine Jak2 (Tyr1007/1008) from
Cell Signaling (Beverly, MA), hPR Ab-7 (clone 7), and actin (clone ACTN05)
from Neomarkers (Freemont, CA), and FLAG-M2 monoclonal antibody from
Sigma (St. Louis, MO). Association between PR and Stat3 was studied by
performing coimmunoprecipitation experiments. Total cell lysates (500 g
protein) from C4HD cells, treated and untreated with MPA, were immunopre-
cipitated using the PR mouse monoclonal antibody hPR Ab-7 (clone 7; Neo-
markers). Immunoprecipitations were rocked for 2 h at 4°C, and the immuno-
complexes were then captured by adding protein A-agarose and rocked for an
additional 2 h. Beads were washed three times with lysis buffer and then boiled
for 10 min in sample buffer and subjected to SDS-PAGE. Proteins were elec-
troblotted onto nitrocellulose and probed with an anti-Stat3 antibody (C-20;
Santa Cruz). When the immunoprecipitation-immunoblotting procedure was
reversed, lysates were immunoprecipitated with the anti-Stat3 antibody, and
Western blotting was performed with the anti-PR antibody (Ab-7; Neomarkers).
As a negative control, preimmune rabbit serum was used.
Preparation of nuclear and cytosolic extracts. C4HD and T47D cells were
lysed by scraping at 4°C in buffer A, which contains 10 mM Tris (pH 7.4), 1.5 mM
EDTA, 10% glycerol, 0.5 mM dithiothreitol, 1 mM PMSF, 10 g/ml leupeptin,
5 g/ml pepstatin, 5 g/ml aprotinin, and 5 mM NaF. The homogenate was
centrifuged for 10 min at 1,000  g, and the supernatant fraction (cytosol) was
then collected. The crude nuclear pellet was washed once with buffer A contain-
ing 0.01% NP-40 and centrifuged again at 1,000  g, and the supernatant was
added to the cytosol, which was then centrifuged at 105,000  g for 30 min. The
supernatant yielded the cytoplasmic fraction. The washed crude nuclear pellet
was resuspended in buffer A containing 0.4 M KCl and was later incubated for
30 min at 4°C with resuspension every 10 min. The suspension was centrifuged at
105,000  g (30 min) and diluted with the same volume of buffer A to reduce the
salt concentration.
EMSA. The DNA-binding activity of Stat3 in nuclear cell extracts of C4HD
cells was analyzed by electrophoretic mobility shift assay (EMSA). C4HD cells
were treated for 15 min at 37°C with MPA or MPA-RU486 or were left un-
treated growing in ChFCS. Double-stranded DNA containing the high-affinity
mutant of the sis-inducible element (SIE) from the human c-fos promoter (5G
TGCATTTCCCGTAAATCTTGTCTACA3) (m67) was used as probe. M67
oligonucleotide was end labeled with [-32P]ATP by T4 polynucleotide kinase to
a specific activity of approximately 30,000 to 50,000 cpm/0.1 ng. Twenty micro-
grams of protein from nuclear extracts was incubated for 20 min at room tem-
perature in a total volume of 30 l with 1 ng of the [32P]m67. The DNA-binding
reaction mixture also consisted of 2.5 g poly(dI-dC), as nonspecific competitor
DNA, in a binding buffer containing 10 mM Tris-HCl (pH 7.4), 50 mM NaCl,
10% glycerol, 1 mM dithiothreitol, 5 mM MgCl2, 5 g/l gelatin, 1 mM PMSF,
10 g/ml leupeptin, 5 g/ml pepstatin, and 5 g/ml aprotinin. The specificity of
Stat3-DNA complexes was studied by competition with a 25- and 100-fold mass
excess of unlabeled m67 oligonucleotide and by the lack of competition with a
100-fold mass excess of a mutant m67 with a TTC-to-CCA substitution in the
DNA-binding region (5GTGCATCCACCGTAAATCTTGTCTACA3) (Santa
Cruz). An anti-Stat3 antibody (clone C-20) or an anti-Stat1 antibody (clone
E-23), each from Santa Cruz, was used in the supershift assays at a concentration
of 4 g/assay. Preimmune rabbit serum was used as a control. Samples were
subjected to electrophoresis on nondenaturing 5.5% acrylamide gels (30:1) in
low-ionic-strength TBE buffer (10 mM Tris-borate [pH 7.5], 0.025 mM EDTA).
Gels were preelectrophoresed at 10 mA for 60 min, and samples were run at 20
mA/gel for 120 min at room temperature. To prevent warming of the gels, water
was recirculated through the gel apparatus. Gels were dried without fixation
under vacuum and were autoradiographed by exposure to Kodak X-OMAT film
at 70°C.
In vivo blockage of Stat3 expression. C4HD cells growing in 10 nM MPA were
transiently transfected as already described above with the DN Stat3Y705-F
expression vector and with the empty pRc/CMV vector or remained untreated.
After 48 h of transfection, 106 cells from each experimental group were inocu-
lated s.c. into animals treated with a 40-mg MPA depot in the flank opposite the
cell inoculum. Tumor growth was measured three times a week with a vernier
caliper. Tumor volume (mm3) was calculated as (L  W2)/2, where L 	 length
(mm) and W 	 width (mm). Tumor growth rates were determined as the slopes
of growth curves. Percentage of tumor growth inhibition was calculated by
dividing the mean tumor volume of the animal group injected with C4HD cells
transiently transfected with the DN Stat3Y705-F expression vector, by the mean
tumor volume of control groups, subtracting the resulting value from 1, and
multiplying it by 100. Tumor growth delay was evaluated as T  C, where T and
C are the median times for treated and control tumors, respectively, to reach the
same volume. At day 21, animals from each group were killed and tumors were
removed. Tissues for molecular studies were stored at 80°C, and tissues for
histopathological analysis were fixed in 10% buffered formalin. Samples of liver,
lung, heart, and pancreas were also fixed for histological examination. Compar-
ison of tumor volumes between the different groups for specific times was done
by analysis of variance followed by Tukey’s t test among groups. Linear regres-
sion analysis was performed on tumor growth curves, and the slopes were com-
pared using analysis of variance followed by a parallelism test to evaluate the
statistical significance of differences.
RESULTS
MPA induces Stat3 tyrosine phosphorylation acting through
the classical PR and through a mechanism requiring Jak1,
Jak2, and Src activation. We performed the present study in
an experimental model of hormonal carcinogenesis in which
the synthetic progestin MPA induced mammary adenocarci-
nomas in female BALB/c mice (3, 4, 25, 44). Primary cultures
of the C4HD murine mammary tumor line (3, 4, 25, 44) were
used. As we have already described in detail (19), C4HD ep-
ithelial cells derive from a ductal, progestin-dependent mam-
mary tumor line. C4HD cells require MPA administration to
proliferate and express high levels of PR (19). We first inves-
tigated Stat3 expression and tyrosine phosphorylation in
C4HD cells. As shown in Fig. 1, C4HD cells express Stat3 at
the protein level. MPA treatment of C4HD cells for 48 h
induced a two- to threefold up-regulation of Stat3 protein
expression (Fig. 1, first panel), as reported in human breast
cancer T47D cells (26, 43). The progestin antagonist RU486
completely inhibited the stimulatory effect of MPA on Stat3
expression (Fig. 1, first panel). C4HD cells also express Stat1
(Fig. 1, third panel). However, MPA not only had no effect on
Stat1 expression, but in some experiments it even reduced
Stat1 expression slightly (Fig. 1, third panel). We also found
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that MPA treatment of C4HD cells for 5 to 10 min induced
phosphorylation of Stat3 on tyrosine residue 705 by performing
Western blot assays with the specific antiphosphotyrosine Stat3
antibody (Fig. 2A, first part). This effect was completely abol-
ished by RU486 (Fig. 2A, first part). On the other hand, Stat1
showed basal levels of phosphorylation on tyrosine 701, which
remained unaffected by MPA treatment (Fig. 2A, third part).
The involvement of members of the Jak tyrosine kinase family
in cytokine-mediated Stat phosphorylation has been well ac-
knowledged (1). However, the role of Jaks in progestin-
induced Stat3 activation has never been explored. Here, we
found that both Jak1 and Jak2 were expressed in C4HD cells
(Fig. 2A, sixth and eighth parts). MPA treatment resulted in
strong tyrosine phosphorylation of Jak1 and Jak2, observed
as early as 5 min after treatment, which was inhibited by anti-
progestin RU486 (Fig. 2A, fifth and seventh parts, respec-
tively). Similar experiments were conducted with T47D cells.
As shown in Fig. 2B, MPA was able to induce Stat3 tyrosine
phosphorylation in T47D cells, and this effect was abolished by
RU486. MPA treatment of T47D cells also resulted in Jak1
and Jak2 tyrosine phosphorylation, which was blocked by
RU486 (Fig. 2B). Interestingly, although Stat3 tyrosine phos-
phorylation was very transient, Jak activation persisted for at
least 15 min and returned to basal levels at 30 min of MPA
treatment in both the C4HD (Fig. 2A) and T47D (Fig. 2B) cell
lines. To further demonstrate that conventional PR is mediat-
ing nongenomic MPA-induced Stat3 tyrosine phosphorylation,
we used our well-characterized mouse metastatic mammary
tumor line LM3, which lacks PR expression (40). MPA was not
able to induce Stat3 phosphorylation in wild-type LM3 cells
(Fig. 2C). However, as we previously demonstrated (40), treat-
ment of LM3 cells with the type I RTK ligand heregulin
strongly induced Stat3 tyrosine phosphorylation (Fig. 2C). On
the other hand, when we transiently transfected LM3 cells with
a human PRB expression vector, MPA treatment resulted in
strong induction of Stat3 tyrosine phosphorylation, which was
abolished by RU486 (Fig. 2C). We used a similar strategy with
human PR null T47D-Y cells (26). As shown in Fig. 2D, MPA
treatment of T47D-Y cells did not induce Stat3 tyrosine phos-
phorylation. However, when these cells were transfected with
PRB, strong Stat3 tyrosine phosphorylation in response to
MPA was detected (Fig. 2D). RU486 inhibited MPA-induced
Stat3 phosphorylation (Fig. 2D).
We then investigated the participation of Jaks in MPA-
induced Stat3 phosphorylation. For this purpose, C4HD cells
were transiently transfected with 2 g DN Jak1 or DN Jak2
vector (38, 39) and then treated with MPA. Transfection effi-
ciency in C4HD cells, evaluated using the pEGFP-N1 vector,
varied from 65 to 75%, as determined by the percentage of
cells that exhibited green fluorescence 24 h after transfection.
Green fluorescent protein was visualized by direct fluorescence
imaging using confocal laser microscopy. High efficiency of
transfection in our cell cultures induced high levels of DN Jak
expression, shown by an increase in total Jak1 and Jak2 ex-
pression in cells transfected with DN Jak expression vectors,
compared with nontransfected cells (Fig. 3A and B, respec-
tively). As shown in Fig. 3A and B, when DN Jak1 and Jak2
were expressed in C4HD cells, they were able to work domi-
nant negatively against MPA-induced tyrosine phosphoryla-
tion of wild-type Jaks present in C4HD cells. Experiments
done transfecting C4HD cells with increasing amounts of DN
Jak vectors showed that inhibition of wild-type Jak tyrosine
phosphorylation was dose dependent (data not shown). Spec-
ificity of DN Jak action was demonstrated by lack of effect of
the DN Jak2 vector on MPA-induced tyrosine phosphorylation
of endogenous Jak1 (Fig. 3A) and of the DN Jak1 vector on
MPA-induced phosphorylation of endogenous Jak2 (Fig. 3B).
Abolishment of Jak1 and Jak2 activity resulted in inhibition of
the capacity of MPA to induce Stat3 tyrosine phosphorylation
(Fig. 3C, upper parts), clearly showing that both kinases are
involved in the effect of MPA.
The requirement of Src activity for Stat3 activation in breast
cancer cells has already been acknowledged (7, 20, 53, 55, 57).
In addition, accumulating data have shown the ability of pro-
gestin to induce c-Src phosphorylation by a nongenomic mech-
anism in mammary tumor cells (5, 6, 13, 33). Therefore, we
here assessed the effect of MPA on c-Src activity in C4HD
cells. MPA treatment of C4HD cells for 2 to 10 min induced
strong c-Src tyrosine phosphorylation, which was significantly
inhibited by the selective Src family kinase inhibitor PP2 (Fig.
3D). We then explored the role of c-Src in MPA-induced Stat3
tyrosine phosphorylation. As shown in Fig. 3E, inhibition of
Src activity by preincubation of cells with PP2 blocked the
capacity of MPA to induce Stat3 phosphorylation. The above
results show that both Jaks and Src are able to activate Stat3.
To gain further insight into the molecular mechanism through
which these kinases participate in Stat3 tyrosine phosphoryla-
tion, we examined the tyrosine phosphorylation state of Jak1
FIG. 1. MPA up-regulates Stat3 protein expression. Primary cul-
tures of C4HD cells were treated for 48 h in medium with ChFCS
supplemented with 10 nM MPA or MPA–10 nM RU486. Fifty micro-
grams of protein from cell lysates was electrophoresed and immuno-
blotted for Stat3 and Stat1. A Western blot assay using an antiactin
antibody was carried out using identical protein lysates as a control for
the specificity of the effect of MPA. This is a representative experiment
of a total of four in which the standard error of the mean was within
10%. W, Western blot assay.
VOL. 25, 2005 Stat3 ACTIVATION BY PROGESTINS 4829
and Jak2 in C4HD cells pretreated with the Src inhibitor PP2.
We found that Jak1 and Jak2 tyrosine phosphorylation was
effectively inhibited by PP2 (Fig. 3E). These findings indicate
that Jaks are phosphorylated by c-Src in C4HD cells.
MPA induces association between Stat3 and PR. Stats have
been found to be physically associated with several members of
the steroid receptor superfamily, including PR (30, 43). In this
work, we investigated the capacity of MPA to induce associa-
tion between Stat3 and PR by performing coimmunoprecipi-
tation experiments. Protein extracts from C4HD cells were
immunoprecipitated with an anti-PR antibody and immuno-
blotted with an anti-Stat3 antibody. As shown in Fig. 4A, as-
sociation between PR and Stat3 was detected in C4HD cells
growing in 0.1% ChFCS and was dramatically increased by
MPA treatment. Coimmunoprecipitation of Stat3 and PR was
also detected when the immunoprecipitation-immunoblotting
procedure was reversed. Thus, when cell extracts were immu-
noprecipitated with an anti-Stat3 antibody and Western blot-
ting was performed with an anti-PR a clear MPA-induced
association between Stat3 and PR was found (Fig. 4B). Since
we found that Src activity is an absolute requirement for MPA-
induced Jak and Stat3 tyrosine phosphorylation, we explored
Src involvement in the association between PR and Stat3. As
shown in Fig. 4A and B, abolishment of Src activity resulted in
blockage of the capacity of MPA to induce a physical associ-
ation between PR and Stat3.
MPA induces Stat3 nuclear translocation and binding
to DNA. Upon tyrosine phosphorylation, Stats dimerize and
translocate to the nucleus, where they bind DNA and regulate
gene transcription. In order to investigate the effects of MPA
on these events, nuclear and cytoplasmic extracts from C4HD
cells were prepared and Western blot assay was performed
with an anti-Stat3 antibody. While Stat3 was only detected in
the cytoplasmic fraction in untreated cells growing in 0.1%
ChFCS, MPA treatment induced an extensive nuclear translo-
cation of Stat3 (Fig. 5, upper panel). In addition, we found that
inhibition of Src activity by PP2 inhibited MPA-induced Stat3
nuclear translocation (Fig. 5, upper panel). Cellular fraction-
ation was controlled by immunoblotting with either an anti-
PI-3K (Fig. 5, middle panel) or an anti-retinoblastoma (Rb)
(Fig. 5, lower panel) antibody.
We then investigated the capacity of MPA to induce Stat3
binding to DNA, using as a labeled probe a high-affinity mu-
tant of the SIE from the human c-fos promoter (m67), which
binds both Stat3 and Stat1 (11, 56). EMSAs using nuclear
extracts from C4HD cells treated with MPA for 15 min dem-
onstrated that MPA was able to promote formation of DNA-
binding complexes (Fig. 6, left panel). As has been acknowl-
edged in numerous studies (11, 56), three major complexes
were found in C4HD cells corresponding to Stat3 homodimers,
FIG. 2. MPA induces tyrosine phosphorylation by Stat3, Jak1, and
Jak2. Cultures of C4HD (A) and T47D (B) cells were treated with 10
nM MPA or MPA–10 nM RU486 for the indicated times. Fifty mi-
crograms of protein from cell lysates was electrophoresed, and West-
ern blot assays were performed with antiphosphotyrosine 705 Stat3,
antiphosphotyrosine 701 Stat1, antiphosphotyrosine 1022/1023 Jak1,
and antiphosphotyrosine 1007/1008 Jak2 antibodies. Membranes were
then stripped and hybridized with anti-Stat3, -Stat1, -Jak1, and -Jak2
antibodies. This experiment was repeated six times for C4HD cells and
three times for T47D cells with similar results. LM3 (C) or T47D-Y
(D) cells were transfected with PRB or with the empty pSG5 plasmid
or remained untreated. Cells were then stimulated for 5 min with MPA
or pretreated with RU486 before MPA stimulation. LM3 cells were
also treated with heregulin for 10 min. Fifty micrograms of protein
from cell lysates was electrophoresed, and Western blot assays were
performed with antiphosphotyrosine 705 Stat3 (upper parts of panels
C and D). Membranes were then stripped and hybridized with anti-
Stat3 (middle panes of parts C and D) and anti-PR (lower parts of
panels C and D) antibodies. This experiment was repeated three times
with similar results. W, Western blot assay.
4830 PROIETTI ET AL. MOL. CELL. BIOL.
Stat3-Stat1 heterodimers, and Stat1 homodimers (Fig. 6, left
panel). Specificity of the Stats-DNA complexes was demon-
strated by competition with excess unlabeled m67 oligonucle-
otide and by lack of competition with a mutated m67 probe
(Fig. 6, left panel). Stat1 binding to DNA was observed in cells
growing in 0.1% ChFCS, while no increase in the levels of
Stat1-DNA complexes was observed after MPA treatment
(Fig. 6, left panel), in accordance with our finding of basal
Stat1 tyrosine phosphorylation, which remained unaffected by
MPA treatment (Fig. 2). On the contrary, MPA strongly in-
duced the formation of Stat3-DNA complexes, which was com-
pletely abolished by preincubation with RU486 (Fig. 6, left
panel). To confirm the identity of the DNA-binding complexes,
either anti-Stat3 or anti-Stat1 antibodies were included in the
EMSA reaction mixture (Fig. 6, right panel). The use of an
anti-Stat3 antibody (clone C-20) resulted in complete abol-
ishment of the MPA-induced Stat3 homodimer-DNA complex
and dramatically decreased the Stat3-Stat1 heterodimer-DNA
complex abundance (Fig. 6, right panel). This antibody also
induced the formation of a complex with decreased mobility
(Fig. 6, right panel). The Stat1 antibody (clone E-23) was raised
against a Stat1 epitope corresponding to an amino acid se-
quence within the carboxy-terminal SH2 domain sequence
present in both Stat1 and Stat1. The inclusion of this anti-
body in the EMSA reaction mixture eliminated Stat1 homo-
dimer-DNA complexes (Fig. 6, right panel) and induced a
highly significant decrease in Stat3-Stat1-DNA heterodimer
complex abundance (Fig. 6, right panel). As previously re-
ported for this antibody (Fig. 6, right panel) (46, 47), no super-
shift was detected. An equivalent amount of the preimmune
rabbit serum used as a control had no effect (Fig. 6, right panel,
NRS). These data clearly show the presence of Stat3 in MPA-
induced DNA-protein complexes. We found similar results in
the EMSAs using the 2-macroglobulin probe, which contains
the GAS element in the 2-macroglobulin enhancer (49, 56),
as has been previously reported in HEPG2 cell types (49).
MPA induces Stat3 transcriptional activation through a
Jak1-, Jak2-, and Src-dependent pathway. To investigate the
capacity of MPA to induce the transcriptional activation of
Stat3, C4HD cells were transiently transfected with a luciferase
reporter plasmid containing four copies of the m67 high-affin-
ity binding site (11, 56) and a -galactosidase expression vector
FIG. 3. Jak1 and Jak2 are involved in MPA-induced Stat3 phos-
phorylation. C4HD cells were transiently transfected with 2 g of DN
Jak1 or DN Jak2 vector and then treated with MPA for 5 min or left
untreated. Fifty micrograms of protein from cell lysates was electro-
phoresed, and Western blot assays were performed with antiphospho-
tyrosine Jak1 (A, upper part) or antiphosphotyrosine Jak2 (B, upper
part) antibodies. Membranes were then stripped and hybridized with
anti-Jak1 (A, lower part) and anti-Jak2 (B, lower part) antibodies.
(C) Fifty micrograms of protein from cells transfected with the DN
Jak1 (left part) or the DN Jak2 (right part) vector and subsequently
treated with MPA for 5 min or left untreated was electrophoresed, and
Western blot assays were performed with antiphosphotyrosine Stat3
(upper parts). Membranes were then stripped and hybridized with
anti-Stat3 (lower parts) antibodies. (D) C4HD cells were treated with
MPA for the indicated times or preincubated with the selective Src
family kinase inhibitor PP2 or RU486 for 90 min and then treated with
MPA. Fifty micrograms of protein from cell lysates was electropho-
resed and immunoblotted with an antiphosphotyrosine c-Src antibody
(upper part). Membrane was then stripped and hybridized with anti-
c-Src antibody (lower part). (E) C4HD cells were preincubated with
the selective Src family kinase inhibitor PP2 for 90 min and then
treated with MPA for 5 min. Fifty micrograms of protein from cell ly-
sates was electrophoresed and immunoblotted with antiphosphoty-
rosine Stat3, antiphosphotyrosine Jak1, and antiphosphotyrosine Jak2
antibodies. Membranes were then stripped and hybridized with anti-
Stat3, anti-Jak1, and anti-Jak2 antibodies, respectively. These experi-
ments were repeated three times with similar results. W, Western blot
assay.
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as an internal control. Treatment of C4HD cells with MPA
induced Stat3 transcriptional activation that was completely
inhibited by preincubation with RU486 (Fig. 7A). Blockage of
Jak1 and Jak2 activities by the use of a DN Jak1 or Jak2
expression vector and of Src activity with PP2 also inhibited the
capacity of MPA to activate the m67-Luc reporter plasmid
(Fig. 7A). Comparable results were obtained with T47D cells,
in which MPA also induced Stat3 transcriptional activation.
RU486 pretreatment, transfection with a DN Jak1 or Jak2
expression vector, and PP2 preincubation all abolished the
capacity of MPA to activate the m67-Luc reporter in T47D
cells (Fig. 7B). Similar results with both C4HD and T47D cells
were obtained by using a luciferase reporter plasmid contain-
ing three copies of the Ly6E Stat1 and Stat3 binding site (10)
in the transient-transfection assays (data not shown).
Stat3 activity is a requisite in MPA-induced proliferation of
C4HD cells. To investigate the correlation between MPA-
FIG. 4. MPA induces association of Stat3 with PR. (A) C4HD cells
were treated with 10 nM MPA for the indicated times or preincubated
with PP2 before MPA treatment for 5 min, and PR was immunopre-
cipitated from 500 g of protein extracts. As a control, lysates were
also immunoprecipitated with normal mouse serum (NMS). Immuno-
complexes were subjected to SDS-PAGE and analyzed by Western
blotting with an anti-Stat3 antibody (upper part). Twenty micrograms
of protein from cell extracts was directly immunoblotted with the Stat3
antibody (last lane, upper part). Identical aliquots of each immuno-
precipitate were subjected to immunoblot analysis with anti-PR anti-
body to verify that nearly equal amounts of immunoprecipitated pro-
teins were loaded (lower part). (B) Protein lysates (500 g) from cells
treated as indicated in panel A were immunoprecipitated with an
anti-Stat3 antibody or with normal rabbit serum (NRS). Immunocom-
plexes were subjected to SDS-PAGE and analyzed by Western blotting
with an anti-PR antibody (upper part). Twenty micrograms of protein
from cell extracts was directly immunoblotted with the PR antibody
(last lane, upper part). Identical aliquots of each immunoprecipitate
were subjected to immunoblot analysis with anti-Stat3 antibody to
verify that nearly equal amounts of immunoprecipitated proteins were
loaded (lower part). This is a representative experiment out of a total
of three. W, Western blot assay; IP, immunoprecipitation.
FIG. 5. MPA induces Stat3 nuclear translocation. C4HD cells were
treated with 10 nM MPA for the time indicated or were pretreated
with PP2 before MPA stimulation. Nuclear (nuc) and cytosolic (cyt)
fractions were prepared, and 30 g of protein from cell extracts was
analyzed by Western blot assay for Stat3 expression level. Membranes
were then stripped and hybridized with an anti-p85 PI-3K subunit anti-
body (middle) or an anti-retinoblastoma (Rb) antibody (bottom) in
order to control cellular fractionation efficiency. W, Western blot assay.
FIG. 6. MPA induces Stat3 binding to the high-affinity mutant of
the SIE from the human c-fos promoter. C4HD cells were treated for
15 min at 37°C with MPA or MPA-RU486 or were left untreated grow-
ing in ChFCS. Twenty micrograms of protein from nuclear extracts was
incubated for 20 min at room temperature with 1 ng of 32P-labeled
double-stranded DNA containing the high-affinity mutant of the SIE
from the human c-fos promoter (5GTGCATTTCCCGTAAATCTTG
TCTACA3) (m67) used as a probe and analyzed by EMSA. The
specificity of the Stat3-DNA complexes is shown by competition with
25- and 100-fold mass excesses unlabeled m67 oligonucleotide and by
the lack of competition with a 100-fold mass excess of mutant m67
(100xm67 mut). The right panel shows a supershift analysis that was
performed by including either anti-Stat3 or anti-Stat1 antibodies. An
equivalent amount of preimmune rabbit serum was used as a control in
the EMSA reaction mixture (NRS [normal rabbit serum]). This exper-
iment was repeated six times with similar results. wt, wild type.
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induced Stat3 activation and cell growth, C4HD cells were
transiently transfected with a DN Stat3 expression vector,
Stat3Y705-F (10, 23, 28), which carries a tyrosine-to-pheny-
lalanine substitution at codon 705 that reduces phosphoryla-
tion on tyrosine of the wild-type Stat3 protein, therefore in-
hibiting both dimerization and DNA binding of Stat3. C4HD
cells were also transfected with a constitutively activated Stat3
mutant, Stat3-C, which dimerizes spontaneously, binds to
DNA, and activates transcription (11). Proliferation of trans-
fected C4HD cells was evaluated by PI staining and flow cy-
tometry analysis. As shown in Fig. 8A (middle parts, bottom),
expression of the Stat3Y705-F mutant had an inhibitory effect
on MPA-induced growth of C4HD cells, compared with MPA-
stimulated C4HD cells transfected with the empty vector
(middle parts, top). On the other hand, transfection with the
constitutively activated Stat3-C vector (Fig. 8A, right part)
resulted in MPA-independent proliferation with a percentage
of cells in the S and G2/M phases comparable to the one in
MPA-treated cells, transfected with the empty vector (Fig. 8A,
middle parts, top). Interestingly, profiles of PI staining showed
a significant subdiploid peak in C4HD cells transfected with
the Stat3Y705-F mutant vector (Fig. 8A, middle parts, bot-
tom), compared with C4HD cells transfected with the empty
vector (Fig. 8A, middle parts top), indicating a higher percent-
age of apoptotic cells. To further explore this finding, apoptosis
was investigated through cell surface binding of fluorescent
Annexin V, as an early indicator of programmed cell death. As
shown in Fig. 8B, the level of apoptosis in Stat3Y705-F-trans-
fected cells was found to increase significantly (right parts,
bottom), compared with empty-vector-transfected cells (right
parts, top). As a whole, our results indicate that Stat3Y705-F-
mediated growth inhibition of C4HD cells involves both cell
cycle arrest and apoptosis.
Previous reports (11, 14) have identified members of the
Bcl-2 family of antiapoptotic regulatory proteins as being en-
coded by Stat3-regulated genes. Here, we investigated Bcl-xL
gene expression in C4HD transfected with either Stat3Y705-F
or Stat3-C plasmids. MPA treatment of C4HD cells resulted in
up-regulation of Bcl-xL protein expression (Fig. 8C), in accor-
dance with previous results demonstrating progesterone induc-
tion of Bcl-xL expression in breast cancer cells (34). As shown
in Fig. 8C, transfection with Stat3Y705-F resulted in significant
inhibition of MPA-induced Bcl-xL expression. Inhibition of Src
activity by preincubation of cells with PP2 also induced a de-
crease in MPA-induced Bcl-xL protein (Fig. 8C). On the other
hand, the constitutively activated Stat3-C mutant induced an
increase in Bcl-xL protein levels, comparable to the effect ex-
erted by MPA (Fig. 8C).
Expression and function of Stat3Y705-F and Stat3-C plas-
mids under the conditions described above, in which they mod-
ulate C4HD cell growth, were then assessed. Expression of
either Stat3Y705-F or Stat3-C in transfected C4HD cells was
studied by Western blot assay with an anti-FLAG M2 antibody
since both Stat3Y705-F and Stat3-C are tagged at the carboxyl-
terminal site with the FLAG epitope (Fig. 8D, upper part).
Compared with the nontransfected cells, the levels of Stat3
were markedly higher after transfection with both plasmids
(Fig. 8D, lower part). As a control of Stat3Y705-F function,
Fig. 8E shows that when expressed in C4HD cells, Stat3Y705-F
was able to work dominant negatively against MPA-induced
tyrosine phosphorylation of Stat3. Specificity of Stat3Y705-F
action was demonstrated by its lack of effect on Stat1 consti-
tutive phosphorylation on tyrosine 701 (Fig. 8F). In addition,
the capacity of MPA to induce transcriptional activation of
endogenous Stat3 was completely inhibited by Stat3Y705-F
expression, as shown in the transient-transfection assay with
the m67-Luc reporter plasmid (Fig. 8G). In contrast, Stat3-C
expression resulted in activated transcription of the reporter
gene in cells untreated with MPA (Fig. 8G). As happened with
DN Jak transfection, experiments done by transfecting C4HD
FIG. 7. MPA induces Stat3 transcriptional activation. C4HD (A)
and T47D (B) cells were transiently transfected with 2 g/well of a luc-
iferase reporter plasmid containing four copies of the m67 high-affinity
binding site and with 1 g/well of a CMV-gal expression vector as an
internal control. In the indicated lanes, C4HD cells were cotransfected
with the DN Jak1 and DN Jak2 expression vectors or pretreated with
PP2. Cells were also transfected with a pTATA-Luc reporter lacking
the m67 insertion. The total amount of transfected DNA was standard-
ized by adding the empty vector. After transfection, cells were treated
with MPA and MPA-RU486 at 37°C for 48 h or left untreated growing
in ChFCS. C4HD cells were then harvested and lysed. Luciferase and
-galactosidase activities were measured as described in Materials and
Methods. Results are presented as n-fold induction of luciferase ac-
tivity with respect to cells growing in ChFCS. The data shown repre-
sent the mean of six independent experiments 
 the standard error of
the mean. For b versus a and c versus b, P  0.001.
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cells with increasing amounts of Stat3Y705-F showed that in-
hibition of MPA-induced tyrosine phosphorylation of Stat3
and of the capacity of MPA to induce transcriptional activation
of endogenous Stat3 was dose dependent (data not shown).
In vivo blockage of Stat3 expression results in C4HD tumor
growth inhibition. We have already demonstrated that prolif-
eration in our model system is driven by a complex cross talk
between progestins and growth factors pathways (3, 4, 25, 44).
In the present work, we found that Stat3 is yet one more player
in this scenario, since MPA-induced Stat3 transcriptional ac-
tivation (Fig. 7) is a requisite for MPA stimulation of C4HD
cell growth (Fig. 8). Therefore, we here addressed the effect of
targeting Stat3 in in vivo growth of C4HD breast tumors. For
this purpose, C4HD cells growing in 10 nM MPA were tran-
siently transfected with the DN Stat3Y705-F expression vector
or with the empty pRc/CMV vector or were left untreated.
After 48 h of transfection, 106 cells from each experimental
group were inoculated s.c. into animals treated with a 40-mg
MPA depot in the flank opposite the cell inoculum, and tumor
FIG. 8. Stat3 is involved in MPA-induced proliferation of C4HD
cells. (A) C4HD cells were transiently transfected with 2 g DN Stat3
expression vector, Stat3Y705-F, with 2 g constitutively activated Stat3
mutant, Stat3-C, or with 2 g empty pRc/CMV vector, as a control, for
48 h. Cells were treated with MPA for another 48 h or remained un-
treated and were then stained with PI and analyzed for cell cycle
distribution by flow cytometry. The percentages of total cells in the cell
cycle phases are indicated. (B) C4HD cells were transiently transfected
with 2 g DN Stat3 expression vector or with 2 g empty pRc/CMV
vector, as a control, for 48 h. Cells were treated as described for panel
A, and cell surface Annexin V binding was measured by flow cytom-
etry. (C) Fifty micrograms of protein from lysates of cells transfected
with Stat3Y705-F, Stat3-C, and empty pRc/CMV plasmids and from
nontransfected cells, treated with MPA for 48 h or left untreated, was
electrophoresed, and Western blot assays were performed with an anti
Bcl-xL antibody (upper part). Membrane was then stripped and hy-
bridized with an antiactin antibody (lower part). (D) Fifty micrograms
of protein from lysates of cells treated as described for panel C and
stimulated or not with MPA for 5 min was electrophoresed, and West-
ern blot assays were performed with an anti-FLAG M2 antibody (up-
per part). Membrane was then stripped and hybridized with an anti-
Stat3 antibody (lower part). (E) Fifty micrograms of protein from
C4HD cells transfected with 2 g Stat3Y705-F vector or with empty
pRc/CMV plasmid and subsequently left untreated treated or with
MPA for 5 min was electrophoresed, and Western blot assays were
performed with antiphosphotyrosine Stat3 antibody (upper part).
Membranes were then stripped and hybridized with anti-Stat3 anti-
bodies (lower part). (F) Fifty micrograms of protein from C4HD cells
transfected with 2 g Stat3Y705-F vector and then treated with MPA
for 5 min or left untreated was electrophoresed, and Western blot as-
says were performed with antiphosphotyrosine 701 Stat1 antibody (up-
per part). Membrane was then stripped and hybridized with anti-Stat1
antibody (lower part). Experiments described in panels A to F were
repeated three times with similar results. W, Western blot assay. (G)
C4HD cells were transiently transfected with 2 g/well of the m67-Luc
reporter plasmid and with 1 g/well of a CMV-gal expression vector
as an internal control. In the indicated lanes, C4HD cells were co-
transfected with either Stat3Y705-F or Stat3-C plasmid. The total
amount of transfected DNA was standardized by adding the empty
vector. After transfection, cells were treated when indicated with MPA
for 48 h and were then harvested and lysed. Luciferase and -galac-
tosidase activities were measured as described in Materials and Meth-
ods. Results are presented as n-fold induction of luciferase activity with
respect to cells growing in ChFCS. Data shown represent the mean of
two independent experiments 
 the standard error of the mean. For b
versus a and c versus b, P  0.001. FITC, fluorescein isothiocyanate.
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width and length were measured three times a week in order to
calculate volume. All mice (n 	 9) injected with C4HD cells
transfected with the pRc/CMV vector or injected with wild-
type C4HD cells (n 	 9) developed tumors which became
palpable after 8 days of inoculation. On the contrary, only four
out of nine mice injected with C4HD cells transfected with the
DN Stat3Y705-F expression vector developed tumors, with a
delay of 3 days in tumor latency compared with tumors from
control groups. The mean volume of tumors developed from
DN Stat3Y705-F-transfected C4HD cells was significantly
lower than that of tumors from both control groups (Fig. 9).
Tumor growth rates, determined as the slopes of growth
curves, were significantly lower in tumors developed from DN
Stat3Y705-F-transfected C4HD cells than those of control
groups (Table 1). At day 21, animals in each group were killed
and tumors were excised. Results are summarized in Table 1.
Both tumor growth and growth rates were found to decrease
significantly in tumors developed from DN Stat3Y705-F-trans-
fected C4HD cells (Table 1). At day 21, a delay of 7 days
in tumor growth was observed in mice injected with DN
Stat3Y705-F-treated cells with respect to tumors developed in
mice injected with wild-type C4HD cells and of 6 days with
respect to tumors growing in mice injected with pRc/CMV
vector-transfected cells. No statistically significant differences
were found either in tumor growth, in growth rates, or in
growth delay between tumors growing in mice injected with
wild-type C4HD cells and tumors growing in mice injected with
pRc/CMV vector-transfected cells (Table 1). Histopathologi-
cal analysis was performed by hematoxylin-and-eosin staining
of histological sections obtained from tumors excised at day
FIG. 9. In vivo blockage of Stat3 expression. (A) C4HD cells grow-
ing in 10 nM MPA were transiently transfected with the DN Stat3Y705-
F expression vector () or the empty pRc/CMV vector (■) or remained
untreated (Œ), as described in the legend to Fig. 8. After 48 h of
transfection, 106 cells from each experimental group were inoculated
s.c. into animals treated with a 40-mg MPA depot in the flank opposite
the cell inoculum, and tumor width and length were measured three
times a week in order to calculate volume as described in Materials and
Methods. Each point represents the mean volume 
 the standard
error of nine independent tumors for each control group and of four
tumors that developed in mice injected with Stat3Y705-F-transfected
cells. (B) One hundred micrograms of protein from tumor lysates was
electrophoresed and immunoblotted with an anti-phospho-Stat3 anti-
body (upper part). Shown are two representative samples of mice in-
jected with C4HD wild-type cells (lanes 1 and 2), C4HD cells trans-
fected with the empty pRc/CMV vector (lanes 3 and 4), and C4HD
cells transfected with the DN Stat3Y705-F expression vector (lanes 5
and 6). Membrane was stripped and hybridized with an anti-Stat3 an-
tibody (lower part). This is a representative experiment out of a total
of three. Densitometric analysis of Stat3 phosphorylated bands from
the four tumors that developed in mice injected with C4HD cells
transfected with the DN Stat3Y705-F vector and from multiple C4HD
tumors that developed in mice injected with either wild-type C4HD
cells or with C4HD cells transfected with the empty pRc/CMV vector
showed a significant decrease in Stat3 tyrosine phosphorylation in tu-
mors from mice injected with cells transfected with the DN Stat3Y705-F
vector, with respect to tumors growing in control animals (P  0.001).
W, Western blot assay. (C) One hundred micrograms of protein from
tumor lysates was electrophoresed and immunoblotted with an anti-
Bcl-xL antibody (upper part). Shown are two representative samples of
mice injected with C4HD wild-type cells (lanes 1 and 2), with C4HD
cells transfected with the empty pRc/CMV vector (lanes 3 and 4), and
TABLE 1. Tumor growth rates on day 21a







 39.09* 7.55 
 1.15* 57.14,b 63.84c
pRc/CMV 235.9 
 52.55† 16.52 
 1.287†
Wild-type C4HD 279.6 
 49.15† 18.92 
 1.597†
a All experimental protocols were performed with mice treated with a 40-mg
s.c. MPA depot in the flank opposite the cell inoculum. Mice were inoculated
with C4HD cells transfected with either the DN Stat3Y705-F expression vector
or the empty pRc/CMV vector and with wild-type C4HD cells. While control
groups contained nine mice each, only four of the nine mice injected with cells
transfected with the DN Stat3Y705-F vector developed tumors. Growth rate was
calculated as the slopes of growth curves. At day 21, tumor volume and percent-
age of growth inhibition in tumors from mice injected with cells transfected with
the DN Stat3Y705-F expression vector with respect to mice injected with the
empty pRc/CMV vector or with wild-type C4HD cells were calculated as de-
scribed in Materials and Methods. * versus †, P  0.001.
b With respect to pRc/CMV treatment.
c With respect to wild-type C4HD treatment.
with C4HD cells transfected with the DN Stat3Y705-F expression
vector (lanes 5 and 6). Membrane was then stripped and hybridized
with an antiactin antibody (lower part), as a control for the specificity
of the DN Stat3Y705-F effect. Densitometric analysis of the Bcl-xL
band from tumors that developed in mice injected with C4HD cells
transfected with the DN Stat3Y705-F, expressed as a percentage of the
control values (i.e., tumors growing in control groups), ranged between
25 and 40% for tumors growing in mice injected with DN Stat3Y705-
F-transfected cells. There was significant inhibition of Bcl-xL expres-
sion in mice injected with DN Stat3Y705-F-transfected cells with re-
spect to mice injected with empty pRc/CMV vector-transfected cells or
with wild-type C4HD cells (P  0.001).
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21. Tumors from mice receiving DN Stat3Y705-F-transfected
C4HD cells showed a significantly lower number of mitoses (0
to 5 mitoses/10 high-power fields) compared to tumors from
animals receiving wild-type C4HD cells or pRc/CMV vector-
transfected C4HD cells, both of which showed over 10 mito-
ses/10 high-power fields. To gain further insight into the mo-
lecular mechanisms involved in inhibition of tumor growth by
Stat3Y705-F transfection, we explored levels of Stat3 tyrosine
phosphorylation and of antiapoptotic Bcl-xL gene expression in
tumor samples. As shown in Fig. 9B, significantly lower levels
of Stat3 tyrosine phosphorylation were found in tumors devel-
oped in mice injected with DN Stat3Y705-F-transfected cells
than in tumors of mice injected with either pRc/CMV vector-
transfected C4HD cells or wild-type C4HD cells. Furthermore,
Bcl-xL expression was dramatically lower in tumors from DN
Stat3Y705-F-transfected cells than that of both control groups
(Fig. 9C).
There were no signs of overt toxicity in mice injected with
DN Stat3Y705-F-transfected C4HD cells. In addition, we ob-
served no weight loss in mice receiving DN Stat3Y705-F-trans-
fected cells, which shows good tolerance by animals. Histolog-
ical examination of the liver, lung, heart, and pancreas did not
reveal any pathological changes (data not shown).
DISCUSSION
In the present study, we have demonstrated that MPA up-
regulates Stat3 protein expression in C4HD mammary tumor
cells, our experimental model of progestin-induced mammary
carcinogenesis. This effect was completely inhibited by the
progestin antagonist RU486, indicating involvement of classi-
cal PR. The ability of progestin to modulate Stat expression in
breast cancer cells has been previously found by Lange et al.
(26) and by Richer et al. (43), who demonstrated that treat-
ment of T47D cells with the synthetic progestin R5020 resulted
in up-regulation of Stat3, Stat5a, and Stat5b protein levels.
These authors also found a constitutive association between
Stat5 and PRB in HeLa cells transfected with the B isoform of
PR (43). Recently, progesterone was found to induce Stat5a
expression in MDA-MB-231 breast cancer cells transfected
with PR (29). Functional interaction between progestins and
Stat3 was also found in decidual cells (30). Thus, progesterone
enhanced cytoplasmic Stat3 stores in the decidualized meso-
metrium during pregnancy in rats (30), and this effect was
inhibited by RU486, showing that Stat3 is a progesterone-
dependent protein. Association between PR and Stat3 in de-
cidualized mesometrium has also been found (30). Regarding
Stat1, our results showing that MPA not only had no effect on
Stat1 expression but even reduced it slightly are in accordance
with those previously reported for T47D cells (43). Since MPA
exerts a strong proliferative stimulus in C4HD cells, our pres-
ent findings add further support to accumulating evidence fa-
voring a growth inhibitory role of Stat1 (7, 9, 55).
Here, we have for the first time demonstrated that proges-
tins induce rapid Stat3, Jak1, and Jak2 tyrosine phosphoryla-
tion. Moreover, MPA stimulates association between PR and
Stat3, Stat3 nuclear translocation, binding to DNA, and tran-
scriptional activation. All these effects were abrogated by
RU486, indicating involvement of the classical intracellular
PR. Our studies with PR-null LM3 and T47D-Y cells, in which
MPA was not able to induce Stat3 tyrosine phosphorylation,
and the finding that transfection of these cells with PRB re-
stored the effects of MPA further showed the involvement of
conventional PR in progestin-induced Stat3 tyrosine phos-
phorylation We found these results particularly interesting be-
cause of two reasons. First, because they provide support to
accumulating evidence showing Stat3 activation in breast can-
cer cells. In fact, constitutive Stat3 tyrosine phosphorylation
and DNA-binding activity have been found in breast cancer
cell lines and in breast tumor samples (12, 20, 28, 41, 53).
Interestingly, a high frequency of constitutive Stat3 activation
has been reported in human breast cancer cell lines possessing
elevated levels of EGF-R (45). Second, because we have for
the first time uncovered several rapid or nongenomic effects of
progestin, i.e., the capacity of MPA to induce Stat3, Jak1, and
Jak2 tyrosine phosphorylation in both mouse and human
breast cancer cells. Evidence of the capacity of progestins to
promote Jak2 tyrosine phosphorylation was provided in pivotal
studies by Lange et al. (26) and Richer et al. (43). However, in
these studies, short-term treatment of T47Dco cells failed to
induce Jak2 tyrosine phosphorylation, which instead became
readily detectable after 48 h of R5020 stimulation. Differences
between the T47D cell clones used could account for the dis-
crepancy. Nevertheless, it is worth pointing out that either
through transcriptional effects (26, 43) or through the rapid,
nongenomic mechanism we have described here, progestins
are able to modulate Jak2 phosphorylation in breast cancer
cells. From our studies with DN Jak1 and Jak2 expression
vectors, it is clear that progestins induce Stat3 tyrosine phos-
phorylation by a Jak-dependent pathway. It should be noted
that while MPA-induced Stat3 tyrosine phosphorylation is very
transient, Jak activation persists for at least 15 min and returns
to basal levels after 30 min of MPA treatment in both C4HD
and T47D cells. Prolonged Jak activation may reflect involve-
ment of Jaks in other signaling pathways, activated by MPA by
a nongenomic mechanism, besides induction of Stat3 tyrosine
phosphorylation.
In the present work, we have also assessed the role of c-Src
in progestin-induced Stat3 activation in C4HD cells. We were
interested in c-Src because a series of previous reports had
shown the requirement of Src activity for Stat3 activation in
breast cancer cells (7, 20, 53, 55, 57). In addition, accumulating
data showed the ability of progestin to induce Src phosphory-
lation by a nongenomic mechanism in mammary tumor cells
(5, 6, 13, 33). Interestingly, we here found that 2 min of MPA
treatment of C4HD cells induced strong c-Src tyrosine phos-
phorylation in C4HD cells. Blockage of Src activity inhibited
both the capacity of MPA to induce Stat3 phosphorylation and
transcriptional activation in C4HD and T47D cells. Notably,
we also found that abolishment of Src activity results in inhi-
bition of MPA-induced Jak1 and Jak2 tyrosine phosphoryla-
tion. Therefore, our findings indicate that progestins induce
Stat3 tyrosine phosphorylation via Jak- and Src-dependent
pathways. The molecular mechanism through which Jaks and
Src participate in Stat3 phosphorylation remains to be eluci-
dated. Jaks and Src can be hypothesized to cooperate in the
activation of Stat3 in C4HD cells, as described in other breast
cancer cells (20). Our findings led us to hypothesize a mecha-
nism in which Src, activated by progestin binding to the clas-
sical nuclear PR, acts as the upstream kinase for phosphory-
4836 PROIETTI ET AL. MOL. CELL. BIOL.
lation of Jak1 and Jak2. We hereby propose two possible
molecular mechanisms downstream to this event, consistent
with results in our model system. First, both Src and Jaks might
act as kinases for Stat3. Second, activated Jaks might serve to
recruit Stat3 to Src, which in turn could directly phosphorylate
Stat3. A mechanism like the latter has already been proposed
in v-Src-transformed NIH 3T3 cells (57). Interestingly, we also
unraveled several events in the molecular mechanism of MPA-
induced Stat3 activation. Thus, we found that MPA-mediated
Src activation, which in turn induces Stat3 tyrosine phosphor-
ylation, is a requirement for Stat3 nuclear translocation and
association with PR.
Here have here provided the first demonstration that pro-
gestins are able to induce transcriptional activation of Stat3 in
both mouse and human breast cancer cells. As expected from
results with Stat3 tyrosine phosphorylation, assessment of the
molecular mechanism involved in MPA-stimulated Stat3 tran-
scriptional activity in C4HD and T47D cells showed that it is
mediated by the classical nuclear PR and that it requires Jak1,
Jak2, and Src activities. Similarly, Src and the Jak family of
tyrosine kinases have been found to cooperate in mediating
constitutive Stat3 activation in several human breast cancer
cell lines (20).
We have already demonstrated that proliferation in our
model system is driven by a bidirectional interaction between
progestins and growth factors pathways (3, 4, 25, 44). In the
present work, we found that Stat3 is yet another player in this
scenario, since MPA-induced Stat3 transcriptional activation
(Fig. 7) is a requisite for MPA stimulation of C4HD cell
growth (Fig. 8). Thus, transfection of C4HD cells with the DN
Stat3 expression vector Stat3Y705-F (10, 23, 28) strongly in-
hibited MPA-induced proliferation by inducing cell cycle arrest
and apoptosis. These findings, providing the first evidence that
Stat3 participates in progestin-induced breast cancer growth,
are in line with accumulating evidence showing involvement of
Stat3 in the proliferation of breast cancer cells. Thus, in several
breast cancer cell lines possessing activated Stat3, pharmaco-
logical inhibitors of Src and Jaks, whose activation is a require-
ment for Stat3 phosphorylation and DNA-binding capacity,
resulted in abrogation of cell growth (12, 20), with a significant
increase in the percentage of cells undergoing apoptosis (12,
20). In addition, induction of apoptosis and inhibition of cell
growth were observed by transfection of breast tumor cells,
displaying constitutive Stat3 activity, with a naturally occurring
DN Stat3 form, Stat3, or with DN Stat3Y705-F and DN
Stat33E/V expression vectors (12, 20, 28). Very recently, a
dramatic increase in Stat3 tyrosine phosphorylation with con-
fluence was found in normal mammary cells, as well as in
breast cancer cells (53). Confluence-dependent Stat3 activa-
tion was dependent on cell-to-cell contact and on Jak activity
but did not require functional Src (53). On the other hand, we
have demonstrated that transfection with a constitutively acti-
vated Stat3 form, Stat3-C (11), induced progestin-independent
proliferation of breast cancer cells. This is the first evidence of
a direct link between hormone-independent growth of breast
tumors and Stat3 activity. Our results agree with previous stud-
ies with the constitutively activated Stat3-C mutant that proved
that Stat3 has an intrinsic capacity to induce cell transforma-
tion. Thus, rodent fibroblasts expressing Stat3-C form colonies
in soft agar and induce tumors in nude mice (11). Moreover, it
has recently been shown that Stat3-C transforms immortalized
human mammary epithelial cells which then acquire the ca-
pacity to develop tumors in irradiated nonobese diabetic-se-
vere combined immunodeficient mice (17).
Members of the Bcl-2 family of antiapoptotic regulatory
proteins have been identified as being encoded by Stat3-regu-
lated genes, under conditions in which Stat3 modulates cell
growth and survival (11, 14). Thus, constitutive Stat3 activation
results in Bcl-xL expression in a range of tumor cells (55) that
directly correlates with induction of proliferative responses by
Stat3 (reviewed in references 41 and 55). Conversely, blockage
of Stat3 activation or transfection with DN Stat3 variants re-
sulted in induction of apoptosis, inhibition of tumor growth,
and down-regulation of Bcl-xL (2). In our present work, we
found that MPA-induced up-regulation of Bcl-xL protein ex-
pression in C4HD cells was inhibited by transfection with
Stat3Y705-F. In addition, blockage of Src activity resulted also
in significant inhibition of MPA-induced Bcl-xL expression,
further demonstrating the involvement of Stat3 in progestin-
induced Bcl-xL expression. On the other hand, transfection of
C4HD cells with constitutively activated Sta3t-C mutant in-
duced an increase in Bcl-xL protein levels, comparable to the
effect exerted by MPA. These findings are consistent with
a mechanism of malignant transformation in which persis-
tent MPA-induced Stat3 activation might contribute to tumor
growth by preventing apoptosis of C4HD cells. Blockage of
Stat3 activity by transfection of DN Stat3Y705-F would there-
fore result in inhibition of MPA-induced growth by sensitizing
tumor cells to apoptosis.
Finally, our results demonstrated that blockage of Stat3 ac-
tivation by the DN Stat3Y705-F expression vector resulted in
inhibition of in vivo breast tumor growth in our model of
immunocompetent mice. We have used an experimental strat-
egy that relied on modification of cells ex vivo before mice
inoculation. Thus, C4HD cells were transiently transfected
with the DNStat3Y705-F expression vector and were then
inoculated s.c. into syngeneic mice. No tumors developed
in a significantly high percentage of mice injected with
DNStat3Y705-F-transfected C4HD cells. In addition, the low
percentage of tumors that grew in animals injected with
DNStat3Y705-F-transfected C4HD cells showed a greater de-
lay in tumor formation and significantly lower tumor growth
and growth rates. A likely explanation for the lack of tumor
growth in five out of nine mice injected with DNStat3Y705-F-
transfected C4HD cells is that DNStat3Y705-F induced mas-
sive apoptosis of C4HD cells (Fig. 8B), which absolutely pre-
vented them from growing at the site of injection. On the other
hand, assessment of the mechanisms involved in reduced pro-
liferation of the low percentage of tumors that grew in mice
injected with DNStat3Y705-F-transfected C4HD cells re-
vealed a significantly lower Stat3 tyrosine phosphorylation
compared to control groups. Lack of Stat3 activation was ac-
companied by a dramatic reduction in Bcl-xL protein expres-
sion. To our knowledge, there is only one more study assessing
the effect of inhibition of Stat3 activity in breast tumor growth,
in which G-quartet oligodeoxynucleotides (GQ-ODNs) were
developed to inhibit Stat3 activation by abolishment of the
capacity of Stat3 to bind DNA (22). Systemic administration of
these GQ-ODNs blocked the growth of breast and prostate
tumor xenografts in nude mice (22). Inhibitory mechanisms of
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tumor growth by GQ-ODNs were strikingly similar to those we
have reported in our experimental strategy. Thus, levels of
Stat3 activation and of Bcl-2 and Bcl-xL protein expression
were found to be markedly inhibited and apoptosis was found
to be much higher in tumors from mice receiving GQ-ODNs
compared with tumors from placebo-treated cells (22). We
could not define significantly higher levels of apoptosis in tu-
mors from DNStat3Y705-F-transfected C4HD cells than those
in control groups, using the terminal deoxynucleotidyltrans-
ferase-mediated dUTP-biotin nick end labeling method (data
not shown). Although to some extent this was an unexpected
result, a probable explanation is that the rapidity of the death
process makes it difficult to visualize and to quantify apoptosis.
Our samples were tumors that developed in mice for 21 days.
It could be hypothesized that the mechanism of tumor growth
inhibition in our in vivo experimental approach relies on block-
age of MPA-induced Stat3 activation that results in the abro-
gation of expression of antiapoptotic proteins, such as Bcl-xL,
which in turn triggers apoptosis of breast cancer cells.
In addition to direct regulation of gene expression by trans-
fection with DN variants of Stat3, which might account for the
growth inhibitory properties of DN Stat3, a strong bystander
effect mediated by DN Stat3 expression has been reported.
Thus, a series of previous studies demonstrated that gene ther-
apy by electroinjection of the DN Stat3 expression vector into
preexisting murine melanoma B16 tumors resulted in inhibi-
tion of tumor growth and tumor regression (35, 36). Interest-
ingly, although only 10 to 15% of the tumor cells were trans-
fected in vivo in these studies, the antitumor effect of Stat3
was associated with massive apoptosis of B16 cells, suggesting
a bystander effect (36). Stat3-transfected B16 cells released
soluble factors capable of inducing apoptosis and cell cycle
arrest of nontransfected B16 cells, which suggests that the
bystander effect could be mediated in part by soluble factors
(36). It was very recently demonstrated that blockage of Stat3
in tumor cells increased expression of proinflammatory cyto-
kines and chemokines that activate innate immune cells to
produce immunological danger signals such as nitric oxide and
tumor necrosis factor alpha (54). Inflammatory mediators syn-
thesized as a consequence of the abrogation of Stat3 function
in tumor cells also activate dendritic cells, resulting in tumor-
specific T-cell responses (54). Therefore, antitumor immune
responses might be involved in the bystander effect. Finally,
evidence has been provided demonstrating that inhibition of
angiogenic signals could also mediate the bystander effect of
abrogation of Stat3 signaling (37). Remarkably, all of the
mechanisms mentioned above as mediators of the bystander
effect of abrogation of Stat3 signaling might be able to inhibit
DNStat3Y705-F-transfected C4HD cells in vivo growth. Par-
ticularly interesting is the concept of involvement of a host
immune response in the antitumor effect, since we have worked
with a model of immunocompetent mice, in contrast to the
aforementioned study in which systemic administration of
these GQ-ODNs inhibited the growth of breast tumor xeno-
grafts in nude mice (22). An intriguing question is the mech-
anism mediating the inhibition of Stat3 tyrosine phosphoryla-
tion in tumors arising from DNStat3Y705-F-transfected C4HD
cells. Our in vitro studies showed both a significant increase in
Stat3 expression after transfection of C4HD cells with the
DNStat3Y705-F vector (Fig. 8D) and a direct correlation be-
tween the increase in Stat3 expression after DNStat3Y705-F
transfection and the decrease in the levels of Stat3 tyrosine
phosphorylation (Fig. 8E). It remains to be elucidated whether
the levels of expression of the DNStat3Y705-F vector could be
high enough to account for decreased levels of Stat3 phosphor-
ylation after 21 days of in vivo tumor growth. Another inter-
esting possibility to consider is that soluble factors released by
cells expressing DNStat3Y705-F might result in abrogation of
MPA-induced Stat3 tyrosine phosphorylation.
Here, we have not only unraveled a novel mechanism of
progestin-Stat3 interaction but have also demonstrated novel
nongenomic progestin effects in breast cancer cells directly
associated with proliferation. Our findings have for the first
time demonstrated that progestins are able to induce Stat3
transcriptional activation, which is in turn an obligatory re-
quirement for progestin stimulation of both in vitro and in vivo
breast cancer growth. Accumulated evidence, including our
own results, has shown that breast cancer proliferation is
driven by bidirectional cross talk between steroid hormones
and growth factors. In the present study, we have demon-
strated that Stat3 is yet another player in this scenario. Taking
into account the role of Stat3 as a transcription factor, it could
interact on chromatin with other transcription factors, such as
PR, to regulate gene transcription both in normal proliferation
and in the aberrant growth of malignant cells. On the other
hand, proliferative effects of GFs are mediated by signaling
pathways that ultimately result in activation of transcription
factors. In this context, what makes Stats so attractive is that
they could constitute a convergence point between steroid hor-
mones and GF signaling pathways so that targeting of Stat3
might in turn be an alternative therapy for effective treatment
of breast cancer.
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